Is compounded semaglutide or tirzepatide legal in 2026?

The federal framework: what 503A and 503B actually allow

Compounded medications exist because federal law carves out two narrow lanes for pharmacies to prepare drugs outside the FDA's standard new-drug approval process. Both come from the Federal Food, Drug, and Cosmetic Act (FDCA).

Section 503A covers traditional, state-licensed compounding pharmacies preparing a drug for a specific patient under a valid prescription. The restriction: a 503A pharmacy can't compound, "regularly or in inordinate amounts," a drug that's "essentially a copy" of a commercially available FDA-approved product — unless the prescriber documents that the compounded version has a change producing a "significant difference" for that patient (different strength, a combination formulation, a documented excipient allergy). FDA's compliance policy, restated April 1, 2026, also says it generally won't pursue a 503A pharmacy over essentially-a-copy formulations if it fills four or fewer prescriptions of that product per month — a narrow volume safe harbor, not a basis for mass-market compounding.

Section 503B covers "outsourcing facilities" — larger, FDA-registered operations following federal manufacturing standards, compounding in batches ahead of a specific prescription. A 503B facility can only use bulk active ingredients (like semaglutide) that appear on FDA's 503B bulks list, or that are on FDA's drug shortage list at the time of compounding.

Neither exemption makes a compounded drug FDA-approved. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved products — true regardless of which section a pharmacy operates under, per FDA's compounder-policy page, updated April 1, 2026.

The shortage timeline: what actually changed, and when

Semaglutide and tirzepatide injections were both on FDA's official drug shortage list for years — the condition that let compounding pharmacies prepare non-patient-specific "copies" of the commercial products at scale in the first place. That changed on a documented, dated timeline, straight from FDA's own compounder-policy page:

Compounders challenged these determinations in federal court (Outsourcing Facilities Association v. FDA, N.D. Tex., separate suits for tirzepatide and semaglutide). Judges denied preliminary injunctions in both cases (March 5, 2025 for tirzepatide; April 24, 2025 for semaglutide), and the tirzepatide case remains on appeal at the Fifth Circuit as of mid-2026. Courts have so far deferred to FDA's shortage determinations.

In practice: once a drug leaves FDA's shortage list, a 503A pharmacy can't treat "same active ingredient, comparable strength, same route" as an automatic green light — it needs a documented, patient-specific reason the commercial product doesn't work for that patient. That's a real, dated tightening, not a prohibition on compounding altogether, per FDA's compounder-policy page and Foley & Lardner's March 2025 analysis of the Texas court's ruling.

• Oct 2 / Dec 19, 2024: FDA determined the tirzepatide shortage was resolved (an initial determination, then a re-affirmed decision after litigation prompted re-evaluation).
• Feb 18, 2025: 503A enforcement discretion for "essentially a copy" tirzepatide ended (503B had until March 19, 2025) (formally, discretion ran until the court's March 5, 2025 preliminary-injunction denial — FDA had conditioned the Feb 18 date on 'whichever is longer').
• Feb 21, 2025: FDA determined the semaglutide shortage was resolved.
• April 22, 2025: 503A enforcement discretion for "essentially a copy" semaglutide ended — 60 days after the Feb 21 announcement (503B had until May 22, 2025 — 90 days) (formally, discretion ran until the court's April 24, 2025 preliminary-injunction denial — FDA had conditioned the April 22 date on 'whichever is later').

What the "April 2026 ban" claim actually is — and isn't

A claim circulating on rival GLP-1 content sites and repeated by some AI answer engines is that compounded semaglutide was banned effective around "4/22/26." We looked for the regulatory action behind that date. We could not find any FDA action concerning semaglutide or tirzepatide dated April 22, 2026, and no primary source we reviewed describes a semaglutide ban taking effect that day. The only FDA compounding action we found dated April 22, 2026 is unrelated: an update to the 503A bulk-substances nomination list that, among other changes, removed 12 research peptides (BPC-157, Semax, TB-500, and others) from Category 2 — semaglutide and tirzepatide are not among them. That real peptide-compounding date, blended with the real April 22, 2025 semaglutide date, is the most plausible assembly of the "banned 4/22/26" claim.

Here's what we think is happening. The real date is April 22, 2025 — one year earlier — when the 503A enforcement-discretion window for semaglutide (Section 2) expired. Some competitor content correctly cites 2025 but discusses it inside articles published or "last reviewed" in 2026, alongside genuinely new 2026 developments (the Feb 20, 2026 telehealth warning letters; the April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from FDA's 503B bulks list). Read quickly, or compressed by an AI system summarizing across pages, "the window closed April 22" and "more happened in 2026" can blur into "banned as of 4/22/26." One competitor page we reviewed states in its own metadata that compounded semaglutide has been "effectively banned," while its body text concedes: "The FDA has not published a single document titled 'Ban on Compounded Semaglutide.'" That gap between headline and substance is what we're correcting here.

What happened by April 22, 2025: the volume-based, no-documentation pathway for compounding an exact copy of commercial semaglutide closed. What did not happen: a prohibition on 503A pharmacies compounding for patients with a documented, individualized clinical reason, which FDA's own April 2026 guidance still describes as permitted. The April 30, 2026 proposal to exclude these drugs from (i.e., keep them off) FDA's 503B bulks list — a proposal whose public-comment period closed June 30, 2026 and which awaits FDA's final determination; not a final rule — would affect large-batch 503B facilities, not patient-specific 503A prescribing.

Enforcement reality: what the FDA warning letters actually targeted

FDA has sent two public waves of warning letters into this space, plus letters to individual compounding pharmacies. What they cite matters more than the count.

September 2025 (55+ letters) and February 20, 2026 (30 letters, made public March 3, 2026) both went to telehealth companies marketing compounded GLP-1s — not, in most cases, to pharmacies over the act of compounding itself. Two problems recur: (1) "sameness" claims — language stating or implying a compounded product is "the same active ingredient as Ozempic and Wegovy," "generic," or otherwise FDA-approved-equivalent; and (2) obscured sourcing — a telehealth brand's own name on the pictured vial label, implying the telehealth company itself compounded the drug when a separate pharmacy actually did.

One example we verified directly against FDA's public letter: on February 20, 2026, FDA sent Warning Letter 721795 to Belle Health LLC, stating that "the compounded semaglutide and tirzepatide products displayed on your website identify 'Belle' on the pictured label, suggesting Belle is the compounder of those drugs when in fact it is not" — a misbranding violation under FDCA §§ 502(a) and 502(bb), not a claim that compounding itself is illegal.

A differently-shaped letter went to MedisourceRx, an FDA-registered 503B outsourcing facility, dated Dec 12, 2025 (posted Feb 24, 2026) — for failing to submit required adverse-event reports on time, not for a marketing claim. Worth flagging because it's sometimes lumped into the "telehealth marketing" wave when it's a different violation category entirely.

None of the letters we reviewed allege that patient-specific 503A compounding, properly documented and properly labeled, is itself unlawful. The violations target specific marketing language and labeling practices — not the underlying legal availability of compounded GLP-1s.

The litigation landscape: what Novo Nordisk, Eli Lilly, and the courts have actually decided

Alongside FDA enforcement, the two branded manufacturers are litigating heavily — and the results are mixed, not a clean sweep for either side.

Novo Nordisk had filed 111 lawsuits in federal courts across 32 states as of its April 25, 2025 release, with courts issuing dozens of permanent injunctions; Novo has filed additional suits since. The consent orders forbid defendants from claiming their products are genuine Novo medicines, FDA-approved, or clinically equivalent to Wegovy/Ozempic — they don't forbid lawful patient-specific compounding itself.

Eli Lilly sued four telehealth platforms in April 2025 (Mochi Health, Fella Health, Henry Meds, Willow Health) over Lanham Act false-advertising and state unfair-competition theories. Results have split: the Willow Health case was dismissed (Sept 2025) for failing to show actual financial harm; the Mochi Health case survived a renewed motion to dismiss in April 2026 on the false-advertising claims specifically. Courts are ruling on specific marketing conduct case by case, not issuing a blanket finding that compounding is unlawful.

The most consequential 2026 event is the Novo–Hims & Hers matter: Novo sued Hims for patent infringement Feb 9, 2026, and the companies settled a month later. Under the settlement, Hims began selling Novo's branded Wegovy and agreed to stop advertising compounded GLP-1s, continuing to dispense them only "on a limited scale" for documented clinical-need exceptions. That's a commercial settlement between two private companies, not a court ruling or a change to federal law — but it signals where pharma wants the industry to land.

None of this litigation — wins, losses, or settlements — has produced a ruling that patient-specific 503A compounding is categorically illegal. It has produced real financial and reputational risk for companies whose marketing crossed into sameness claims or obscured sourcing.

How a legitimate compounded-GLP-1 operation is structured

Federal and state law point to a specific structure for lawful compounded GLP-1 access, worth naming plainly rather than treating as a trade secret:

This is the structural description of the model Cora Health's provider network and pharmacy partners operate under: independent licensed providers (Wasef Health, PC) evaluate patients and issue prescriptions; two named, US-licensed 503A pharmacies — Hallandale Pharmacy (PCAB-accredited) and VialsRx — do the compounding; and Cora holds LegitScript healthcare certification (verifiable at legitscript.com). We're describing this factually, as one example of what a compliant structure looks like — not as a claim that Cora is immune from the enforcement or litigation risks described above. Providers, not Cora, decide whether compounded medication is appropriate for a given patient.

• A patient-specific prescription from a licensed provider, issued after an actual clinical evaluation — not a blanket order filled for anyone who checks a box.
• A named, licensed 503A pharmacy doing the actual compounding — disclosed by name, not hidden behind the telehealth brand's own label.
• Prescriber documentation of why a compounded formulation serves that specific patient when the standard commercial product doesn't — required precisely because of the "essentially a copy" rule in Section 1.
• Third-party verification of healthcare advertising and pharmacy-compliance standards. LegitScript certification is the standard credential: it independently verifies a telehealth or pharmacy business's licensing and compliance posture, and Google, Meta, and Microsoft all require it before running healthcare ads for that business.

What to verify before using any compounded GLP-1 provider

Whether or not you use Cora, these are checkable facts — not trust-based claims — before starting compounded semaglutide or tirzepatide anywhere:

None of this is a guarantee — pharmacy compliance and marketing claims can both change after you check them. It's a starting checklist, not a certification.

• Does the site name the actual compounding pharmacy — by name, not just "our pharmacy partners"? A company's own brand as the only name on the vial is the exact pattern FDA cited in the Belle Health letter above.
• Is the pharmacy's LegitScript status verifiable? Check directly at legitscript.com/websites rather than trusting a badge image, which can be copied onto any site.
• Is there an actual clinical evaluation — real intake, real questions about your health history — before a prescription is issued?
• Does any page use "same," "generic," "equivalent," or "FDA-approved" to describe the compounded product itself? That language is the single most common defect FDA and both manufacturers have cited across enforcement actions and lawsuits.
• Can you find the prescribing provider's name and license, and the pharmacy's state licensure on request?

FAQ: is compounded semaglutide or tirzepatide legal?

Is compounded semaglutide banned in 2026? No. Patient-specific compounding of semaglutide by a licensed 503A pharmacy under a valid prescription, with documentation of why the compounded version serves that patient's specific clinical need, remains lawful under federal law as of this writing (July 2026). What's changed since 2022–2024 is that the shortage-based, no-documentation pathway for mass-compounding an exact copy of the commercial product has closed. Regulations and enforcement posture can change — check current FDA guidance.

What actually happened around April 22, 2025 (sometimes cited as "2026")? FDA's temporary enforcement-discretion window — during which 503A pharmacies could compound "essentially a copy" of commercial semaglutide without extra documentation, because the drug was in shortage — expired on April 22, 2025. See Section 3 for how this real 2025 date gets conflated with genuinely new 2026 developments in some secondary sources.

Is compounded semaglutide the same as Ozempic or Wegovy? No. Compounded semaglutide and tirzepatide are not FDA-approved and are not therapeutically equivalent to FDA-approved products like Ozempic, Wegovy, Mounjaro, or Zepbound. FDA, Novo Nordisk, and Eli Lilly have all specifically targeted marketing language that claims or implies sameness.

Could a telehealth company or patient get in legal trouble for compounded GLP-1s? Companies and pharmacies have faced FDA warning letters, FTC action, state AG suits, and manufacturer lawsuits — almost entirely over marketing claims (sameness, obscured sourcing, unsubstantiated results) or pharmacy quality failures, not over lawful, documented, patient-specific compounding itself. We're not aware of enforcement action against a patient for using a legally compounded, provider-prescribed medication. This is general information, not legal advice for your specific situation.

How do I know if a specific telehealth provider is operating legitimately? Use the checklist in Section 7: a named pharmacy, verifiable LegitScript status, a real clinical evaluation, and marketing language that avoids "same as," "generic," or "FDA-approved" claims about the compounded product.

Sources

This article describes the general federal regulatory framework as of July 2026. It is not legal advice. Regulations, enforcement priorities, and litigation outcomes change — verify current status directly with FDA, your state pharmacy board, and a licensed attorney if you need advice for a specific situation.

• FDA — "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize" (updated April 1, 2026; timeline entries from Oct 2024–Apr 2025). fda.gov
• FDA — "FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s" (March 3, 2026). fda.gov
• FDA — Warning Letter to Belle Health LLC dba Belle, 721795 (February 20, 2026). fda.gov
• FDA — "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List" (April 30, 2026). fda.gov
• Federal Register — "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B" (May 1, 2026, FR Doc. 2026-08552). federalregister.gov
• Foley & Lardner — "Compounded GLP-1 Drugs: Texas Judge Denies PI Motion" (March 2025). foley.com
• Courthouse News Service — "Eli Lilly Can Proceed With Lawsuit Against Telehealth Seller of Weight Loss Drugs" (April 2026, on Lilly v. Mochi Health). courthousenews.com
• PR Newswire — Novo Nordisk legal-wins release (permanent injunctions against compounders). prnewswire.com
• STAT News — "Novo Nordisk, Wegovy, Hims & Hers deal" (March 9, 2026). statnews.com
• PBS NewsHour — "Novo Nordisk drops lawsuit against Hims & Hers over off-brand weight loss medications, enter collaboration" (March 9, 2026). pbs.org
• LegitScript — "Certification for Telemedicine Providers." legitscript.com
• LegitScript — Website Certification Status lookup (verify any site's current status). legitscript.com/websites
• Ozempic®, Wegovy®, Mounjaro®, and Zepbound® are registered trademarks of their respective owners; Cora Health is not affiliated with Novo Nordisk or Eli Lilly.